Emerging Treatment Options in Second-Line mNSCLC With HER2 MutationsThe HER2 therapeutic landscape continues to evolve with multiple agents in development, though significant refinement remains needed in areas including line placement and mutation type considerations. Additional agents, including IAM1363 from Iambic, show positive responses in HER2 mutations but demonstrate less durability. The therapeutic window advantage appears to favor zongertinib’s selective approach, though brain metastasis efficacy data continue to evolve across all agents. The principle of using best agents first becomes paramount, particularly considering real-world attrition rates of 25-33% between treatment lines. Additional brain-penetrant TKIs from Cogent and Nuvalent (NVL-330) are advancing through development, further expanding future treatment options.